ABT · Abbott Laboratories

Current Thesis

Abbott Laboratories’ device-led recovery thesis failed its published price test on 2026-09-18, when the $102.61 weekly close breached the $103 shelf; the remaining business question is whether Q3 confirms the sales acceleration behind management’s annual guidance. The $103 threshold was published on 2026-09-06 and remains the relevant test of that earlier thesis.

The narrative is dead in its previously published form — the September 18 close broke the post-Q2 structure despite the September 8 TactiFlex Duo approval. This is an inference about the recovery narrative, not evidence that Abbott’s business has stopped growing. Abbott’s July 16 results reported Q2 comparable sales growth of 4.8% and reaffirmed full-year comparable growth guidance of 6.5%–7.5%. Abbott Q2 results.

The refresh also changes the legal picture: Abbott announced a $385 million settlement on September 14 concerning its 2022 infant-formula recall. That agreement concerns different claims from the preterm-formula settlement discussed in the September 6 coverage. Abbott said the new agreement involved no finding of fault or liability. September 14 announcement.

Bullish and bearish views on Abbott Laboratories

The model's bull view on Abbott Laboratories (ABT), in brief: Ablation approval advances the product cycle. The bear view: The published structure has broken. The adjusted market close of $102.61 on 2026-09-18 was below the $103 post-Q2 shelf identified in the 2026-09-06 research. The original weekly-close invalidation has therefore occurred. Comparable growth trails annual guidance. Abbott’s… Both cases follow in full.

Bull Case

• Ablation approval advances the product cycle. Abbott announced Food and Drug Administration approval of TactiFlex Duo on 2026-09-08. The catheter combines pulsed field ablation and radiofrequency energy; Abbott described broader US commercial adoption as forthcoming, without providing a dated revenue contribution. Abbott approval release.
• Earnings guidance supplied fundamental support. On 2026-07-16, Abbott reported Q2 adjusted diluted earnings per share of $1.31 and raised its full-year range to $5.45–$5.60. Those are company results and guidance; they do not establish that the September price decline has ended. Q2 results.
• The dividend declaration is resolved. Abbott declared $0.63 per share on 2026-09-17. This replaces the September 6 note’s estimated declaration date with a completed event and confirms the unchanged quarterly rate. Dividend announcement.

Bear Case

• The published structure has broken. The adjusted market close of $102.61 on 2026-09-18 was below the $103 post-Q2 shelf identified in the 2026-09-06 research. The original weekly-close invalidation has therefore occurred.
• Comparable growth trails annual guidance. Abbott’s 2026-07-16 release reported Q2 sales growth of 13.0% as reported but 4.8% on its comparable measure, against annual comparable guidance of 6.5%–7.5%. The reported rate does not demonstrate delivery against the comparable-growth promise. Q2 results.
• Legal resolution carries a cash obligation. Abbott’s 2026-09-14 announcement specified a $385 million payment to resolve recall-related government and associated claims. It did not describe that agreement as a settlement of all infant-formula litigation. Settlement announcement.

Setup & Price Structure

The supplied split- and dividend-adjusted series records a $102.61 close and a 14-period relative strength index (RSI) of 20.4 on 2026-09-18. Its three-month price change remains positive at 17.7%, while the close is 23.2% below the supplied 52-week high. These measurements describe different windows; none establishes a reversal after the $103 shelf failed.

Positioning evidence remains limited. The September 6 coverage recorded retail-facing articles dated August 25 and August 27; the September 8 news record reports TD Cowen maintaining a $135 analyst price target. These are observations about coverage and analyst opinion. The sample is too small to support a crowding claim, and current ownership flows, short interest and distance from a rising moving average are missing.

Catalyst Calendar (next 30 days)

• 2026-10-15 — Dividend record date. Abbott’s 2026-09-17 declaration schedules this date for the $0.63 quarterly dividend. It is a confirmed corporate event, with no new operating result attached. Dividend announcement.
• ~2026-10-16, est. Q3 results. This remains the provisional date used in the September 6 coverage, whose trackers disagreed. As checked on 2026-09-20, Abbott’s investor calendar lists no upcoming event; the earnings date is unconfirmed. The relevant comparison is with the 6.5%–7.5% annual comparable-growth guidance issued July 16. Abbott events calendar.

The September 8 TactiFlex announcement supplies no exact commercial rollout date. An October launch day cannot be inferred from its reference to adoption in the coming weeks. Approval announcement.

What Would Change Our Mind

Loss of the July earnings shelf has already ended the earlier recovery case: a weekly close below $103 was the published condition, and the September 18 market close met it at $102.61. A later recovery cannot erase that outcome.

Evidence for a separate recovery case would require a weekly close above the same $103 shelf together with Q3 comparable sales growth above Q2’s 4.8% and reaffirmation of the July 16 annual guidance. This is a conditional research test, not a prediction. Another weekly close below $103 or a reduction in that guidance would contradict the proposed repair.

Correlation Notes

This remains a single-name assessment. The supplied September 18 evidence contains no matched peer-return series from which to measure sector correlation. The September 6 coverage cited a September 2 report attributing medtech weakness to rate expectations, but that third-party explanation does not establish the cause of Abbott’s subsequent decline. Abbott’s September 8 approval and September 14 settlement provide company-specific events; the available observations cannot separate their price effects from a broader sector move.